NCT01195831CompletedPhase 3
Multicentre, Randomized, Investigator-Blinded, Parallel-group Study to Assess the Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis.
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- LEO Pharma
- Enrollment
- 244
- Locations
- 9
- Primary Endpoint
- Patients With "Controlled Disease" in Terms of "Clear" or "Minimal" According to Investigator's Global Assessment of Disease Severity at Week 4.
Study Overview
Brief Summary
The purpose of this study is to compare the clinical efficacy of once daily treatment for 4 weeks with Xamiol® gel (calcipotriol plus betamethasone) with twice daily treatment for 4 weeks with Calcipotriol Scalp Solution in patients with scalp psoriasis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Investigator)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients of either gender between 18 and 65 years of age.
- •A clinical diagnosis of scalp psoriasis which is:
- •of an investigator's assessment of clinical signs of the scalp at least ≥ 2 in one of the clinical signs, redness, thickness and scaliness, and at least 1 in each of the other two clinical signs, and total score ≥ 4,
- •of an extent of 10% or more of the total scalp area,
- •of at least moderate severity according the investigator's global assessment.
- •Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs.
- •The patient must provide signed and dated informed consent before any study related activity is carried out.
Exclusion Criteria
- •Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
- •Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vilgaris, acne rosacea, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers and wounds.
- •Any other inflammatory skin diseases that may confound the evaluation of scalp psoriasis
- •Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 3 months prior to visit 1 and during the study.
- •Systemic treatment with all other therapies than biologicals, with a possible effect on scalp psoriasis (e.g., corticosteroids, vitamin D analogues, retinoids, immunosuppressants) within 4 weeks prior to SV2 or during the study.
- •PUVA therapy within 4 weeks prior to randomisation (visit 1) or during the study.
- •UVB therapy wthin 2 weeks prior to randomisation (visit 1) or during the study.
- •Therapies within 2 weeks prior to SV2 and during the study.
- •Topical treatment of psoriasis on non scalp psoriasis lesions with potent or very potent (WHO group III-IV) corticosteroids,
- •Topical treatment of Immunomodulator, e.g. Tacrolimus,
- •Vitamin D analogues (e.g, calcipotriol, tacalcitol, calcitriol),
- •Any topical treatment of the scalp (except for non-steroid medicated shampoos and emollients,
- •Other types of psoriasis treatment, e.g. Chinese medicine, processed Chinese medicine, or hot spring, etc.
- •Planned initiation of, or changes to concomitant medication that could affect scalp psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the study.
- •Known or suspected hypersensitivity to component(s) of the Investigational Products.
- •Known or suspected abnormality of the calcium homeostasis.
- •Known or suspected severe renal insufficiency or severe hepatic disorders, or severe heart disease.
- •Clinical signs or symptoms of Cushing's disease or Addison's disease.
- •Planned extensive exposure to sun (e.g. when working outdoors) during the study, which may affect scalp psoriasis.
- •Females who are pregnant, or of child-bearing potential and wish to become pregnant during the study, or who are breast-feeding.
- •Females of child-bearing potential with a positive serum or urine pregnancy test at SV
- •Any clinically significant abnormality following review of screening laboratory tests (blood and urine samples), physical examination or blood pressure/heart rate measurement performed at SV
- •Participation in any other interventional clinical trial within 4 weeks prior to randomisation.
Arms & Interventions
Xamiol® gel
Experimental
Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
Intervention: Xamiol® gel (Drug)
Calcipotriol scalp solution
Active Comparator
Calcipotriol (as hydrate) 50 mcg/ml
Intervention: Calcipotriol scalp solution (Drug)
Outcomes
Primary Outcomes
Patients With "Controlled Disease" in Terms of "Clear" or "Minimal" According to Investigator's Global Assessment of Disease Severity at Week 4.
Time Frame: 4 weeks
Investigators made a global assessment of the disease severity by use of a 6-point scale (Clear, Minimal, Mild, Moderate, Severe and Very Severe). Patients with disease severity classified as Clear or Minimal disease after the treatment period (week 4) were rated as having Controlled disease.
Secondary Outcomes
- Patients With "Controlled Disease" in Terms of "Clear" or "Minimal" According to Investigator's Global Assessment of Disease Severity at Week 2(2 weeks)
- Patients With "Controlled Disease" in Terms of "Clear" or "Very Mild" According to Patient's Global Assessment of Disease Severity at Week 2.(2 weeks)
- Patients With "Controlled Disease" in Term of "Clear" or "Very Mild" According to Patient's Global Assessment of Disease Severity at Week 4.(4 weeks)
- Patients With Success (Total Sign Score ≤1) at Week 4(4 weeks)
- For Each Clinical Sign (Redness, Thickness, Scaliness), the Percentage of Patients With Success (Clinical Score=0) at Week 4(4 weeks)
- Patients With Success (Patient's Itching Score=None) at Week 4(4 weeks)
- Evaluation of the Quality of Life(Baseline to weeks 2 and 4)
Investigators
Study Sites (9)
Loading locations...
Similar Trials
Completed
Phase 3
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)Exercise Induced AsthmaNCT00127166Organon and Co154
Completed
Phase 4
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensMigraineNCT05217927Pfizer1,415
Completed
Phase 4
Treatment's Duration of Acute Uncomplicated PyelonephritisFeverUrinary Tract InfectionNCT00873626Assistance Publique - Hôpitaux de Paris310
Completed
Phase 2
A Study of Econazole Foam 1% in Athlete's FootAthlete's FootTinea PedisNCT00768599AmDerma135
Terminated
Phase 2
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous GelAtopic DermatitisNCT05253755DermBiont, Inc.10